NUZ-001

DRUG2 trials

Sponsors

Merit E. Cudkowicz, MD

Conditions

Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS)

Phase 2

HEALEY ALS Platform Trial - Master Protocol

RecruitingNCT04297683

Merit E. Cudkowicz, MDAmyotrophic Lateral Sclerosis

Start: 2020-06-14End: 2028-08-01Target: 1500Updated: 2026-03-27

HEALEY ALS Platform Trial - Regimen I NUZ-001

Enrolling by invitationNCT07410806

Merit E. Cudkowicz, MDAmyotrophic Lateral Sclerosis (ALS)

Start: 2026-02-16End: 2028-08-01Target: 160Updated: 2026-02-17

Related Papers

Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis

JAMA Network Open2025-02-1711 citations

Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

2025-02-178 citations

CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

2025-02-176 citations

Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial.

2025-02-176 citations

Results from the first four regimens of the HEALEY ALS Platform Trial (PL5.004)

Neurology2023-04-254 citations

Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease

BMJ Open2022-07-0134 citations